-
Innovation Ranking
Innovation Ranking – Shenzhen Kangtai Biological Products Co Ltd
Shenzhen Kangtai Biological Products Co Ltd (SKTB) is a biopharmaceutical company that discovers, develops, manufactures, and markets biological products. The company's products include Recombinant Hepatitis B Vaccine, Haemophilus Infuenzae Type B Vaccine, Diphtheria Tetanus Acellular Pertussis and Haemophilus Influenzae Type b Combined Vaccine, Measles and Rubella Combined Vaccine, and others. Its technological innovation through extensive research and development activities. SKTB collaborates with various research institutes such as the National Institutes of Health and Peking Union Medical College to develop vaccines....
-
Product Insights
NewNet Present Value Model: Turnstone Biologics Corp’s TIDAL-01
Empower your strategies with our Net Present Value Model: Turnstone Biologics Corp's TIDAL-01 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: CanSino Biologics Inc’s Pneumococcal Vaccine
Empower your strategies with our Net Present Value Model: CanSino Biologics Inc's Pneumococcal Vaccine report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
AbbVie Inc – Tuas Biomedical Park Biologics Manufacturing Facility Expansion – Central Singapore
The AbbVie Inc – Tuas Biomedical Park Biologics Manufacturing Facility Expansion – Central Singapore involves the expansion of a biologics manufacturing plant with a production capacity of 24,000 liters in Tuas Biomedical Park, Singapore. Equip yourself with the essential tools needed to make informed and profitable decisions with our AbbVie Inc – Tuas Biomedical Park Biologics Manufacturing Facility Expansion – Central Singapore report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Biologic For Crohn’s Disease in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Biologic For Crohn's Disease in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Biologic For Crohn's Disease in Crohn's Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Biological-162 in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Biological-162 in Hepatitis B report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Biological-162 in Hepatitis B Drug Details: Antibody (162) is under development for...
-
Sector Analysis
NewFuture of Pharma – Looking Ahead to 2024
This report provides a summary of the near and long-term future of the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot and prioritize them within your sectors.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nemvaleukin Alfa in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemvaleukin Alfa in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemvaleukin Alfa in Ovarian Cancer Drug Details: Nemvaleukin alfa (ALKS-4230)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nemvaleukin Alfa in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemvaleukin Alfa in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemvaleukin Alfa in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Risankizumab in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Risankizumab in Ulcerative Colitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Risankizumab in Ulcerative Colitis Drug Details: Risankizumab (Skyrizi) is a humanized...